-transparent.png){kind=logo}
In a double-blind study, rolipram, a new phosphodiesterase inhibitor, was com pared to placebo in 20 hospitalized depressed patients. There was a high rate of non- completion (11 out of 20) at 28 days. No difference was found in the clinical improvement between the two groups.
| UI | MeSH Term | Description | Entries |
|---|
Related Publications
M W Rowlands, and
T Silverstone, and
J C Cookson
February 1992,
The Journal of clinical psychiatry,
M W Rowlands, and
T Silverstone, and
J C Cookson
September 1963,
Diseases of the nervous system,
M W Rowlands, and
T Silverstone, and
J C Cookson
June 2001,
International psychogeriatrics,
M W Rowlands, and
T Silverstone, and
J C Cookson
January 1996,
The Journal of neuropsychiatry and clinical neurosciences,
M W Rowlands, and
T Silverstone, and
J C Cookson
June 1995,
Journal of affective disorders,
M W Rowlands, and
T Silverstone, and
J C Cookson
February 2008,
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology,
M W Rowlands, and
T Silverstone, and
J C Cookson
August 1997,
Archives of general psychiatry,
M W Rowlands, and
T Silverstone, and
J C Cookson
August 2014,
Journal of child and adolescent psychopharmacology,
M W Rowlands, and
T Silverstone, and
J C Cookson
January 1995,
Psychopharmacology bulletin,
M W Rowlands, and
T Silverstone, and
J C Cookson
January 2012,
Neuropsychiatric disease and treatment,
